高级搜索

动脉化疗栓塞术预防肝癌根治性切除术后肿瘤复发的成本效果分析

李仕来, 万裴琦, 彭涛, 肖开银, 苏铭, 尚丽明, 徐邦浩, 苏智雄, 叶新平, 彭宁, 黎乐群

李仕来, 万裴琦, 彭涛, 肖开银, 苏铭, 尚丽明, 徐邦浩, 苏智雄, 叶新平, 彭宁, 黎乐群. 动脉化疗栓塞术预防肝癌根治性切除术后肿瘤复发的成本效果分析[J]. 肿瘤防治研究, 2015, 42(04): 350-355. DOI: 10.3971/j.issn.1000-8578.2015.04.007
引用本文: 李仕来, 万裴琦, 彭涛, 肖开银, 苏铭, 尚丽明, 徐邦浩, 苏智雄, 叶新平, 彭宁, 黎乐群. 动脉化疗栓塞术预防肝癌根治性切除术后肿瘤复发的成本效果分析[J]. 肿瘤防治研究, 2015, 42(04): 350-355. DOI: 10.3971/j.issn.1000-8578.2015.04.007
LI Shilai, WAN Peiqi, PENG Tao, XIAO Kaiyin, SU Ming, SHANG Liming, XU Banghao, SU Zhixiong, YE Xinping, PENG Ning, LI Lequn. Cost Effectiveness of Transcatheter Arterial Chemoembolization for Preventing Hepatocellular Carcinoma Recurrence After Radical Resection[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 350-355. DOI: 10.3971/j.issn.1000-8578.2015.04.007
Citation: LI Shilai, WAN Peiqi, PENG Tao, XIAO Kaiyin, SU Ming, SHANG Liming, XU Banghao, SU Zhixiong, YE Xinping, PENG Ning, LI Lequn. Cost Effectiveness of Transcatheter Arterial Chemoembolization for Preventing Hepatocellular Carcinoma Recurrence After Radical Resection[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 350-355. DOI: 10.3971/j.issn.1000-8578.2015.04.007

动脉化疗栓塞术预防肝癌根治性切除术后肿瘤复发的成本效果分析

基金项目: 国家自然科学基金(81160262)
详细信息
    作者简介:

    李仕来(1981-),男,博士,主治医师,主要从事肝癌复发与转移的研究

    通讯作者:

    黎乐群,E-mail:li_lequn@263.net

  • 中图分类号: R735.7

Cost Effectiveness of Transcatheter Arterial Chemoembolization for Preventing Hepatocellular Carcinoma Recurrence After Radical Resection

  • 摘要: 目的 建立肝细胞癌(简称肝癌)根治性切除术后预防性动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗的卫生经济学评价模型。方法 140例肝癌患者根治性切除术后分为TACE组和非TACE组(即门诊随访组),收集两组治疗方案直接医疗成本和治疗效果(复发率及无瘤生存时间),进行成本效果分析、增量成本效果分析和敏感度分析。结果 (1)40例非TACE组患者门诊总平均费用为7 121.44元/人;100例TACE组患者复发前总费用为2 8250.45元/人。(2)非TACE组和TACE组的1、2、3、4、5年复发率比较差异无统计学意义(P>0.05);两组无瘤生存时间比较差异无统计学意义(P=0.322)。(3)非TACE组的成本效果比为389.15元/月,TACE组为1 278.30元/月,增量成本效果比为5 560.27元/月。(4)敏感度分析中非TACE组的成本度效果比为350.84元/月,TACE组为1 215.81元/月,增量成本效果比为5 381.35元/月。结论 从卫生经济学角度,预防肝癌术后复发,预防性TACE并不是最优方案,至少不是每个患者都应该或都适合做,在相同的效果下(复发率、无瘤生存时间)门诊随访治疗可能更经济。

     

    Abstract: Objective To establish the health economics evaluation model of preventative transcatheter arterial chemoembolization(TACE) on hepatocellular carcinoma(HCC) patients after radical resection. Methods A total of 140 HCC patients were divided into TACE group and non-TACE group after radical resection. In TACE group, TACEs were performed; and in non-TACE group, only follow-up visits through outpatient department were performed. Direct medical costs of two groups were collected. Recurrent rate and tumor free survival were picked up as effectiveness. Then cost effectiveness and incremental cost effectiveness were analyzed. At last, the sensitivity analysis was also conducted. Results (1) In non-TACE group, the average cost for the outpatient care was 7 121.44 yuan per patient. Meanwhile, in TACE group, the total cost was 2 8250.45 yuan per patient before tumor recurrences. (2) The tumor free survival rates for 1, 2, 3, 4, 5 years between non-TACE group and TACE group were similar, without significant difference(P>0.05).And the tumor free survivals were also similar between two groups (P=0.322). (3) The cost effectiveness ratio was 389.15 yuan/month in non-TACE group while 1 278.30 yuan/month in TACE group. And the incremental cost effectiveness ratio was 5 560.27 yuan/month. (4) According to the sensitivity analysis, the cost effectiveness ratio was 350.84 yuan/month in non-TACE group while 1 215.81 yuan/month in TACE group. And the incremental cost effectiveness ratio was 5 381.35 yuan/month. Conclusion According to the health economics, the preventative treatment of TACE after radical resection for HCC patients is not the best choice, at least is not suitable for every case. It seems that the outpatient care is more economic under the similar effectiveness, recurrent rate and tumor free survival.

     

  • 宫颈癌是威胁全球女性生命健康的第二大恶性肿瘤,发病率仅次于乳腺癌,全世界每年约有50万的新发宫颈癌病例,其中80%来自发展中国家,且发病率和病死率一直居高不下,宫颈癌的治疗一直是国内外研究的重点领域[1-2]。miRNA是一类单链内源性非编码小分子RNA,能够通过与靶mRNA特异性的碱基配对引起靶mRNA的降解或者抑制其翻译,从而对基因进行转录后的表达调控。目前已经证实miRNA在生物发育和细胞分化中发挥重要作用,越来越多的研究表明,miRNA参与多种细胞生物过程与癌症的发生、发展和转移密切相关[3-5]

    自噬是真核细胞的一种非细胞凋亡性程序性死亡,又被称为Ⅱ型程序性细胞死亡。当细胞受到不良刺激如营养缺乏、内质网应激、氧化应激、细胞器损伤以及细胞死亡的情况下都可以激活自噬信号通路,在多种人类肿瘤中存在细胞自噬活性改变,自噬活性降低促进肿瘤的发生和进展[6-8]。自噬在神经退行性疾病、感染性疾病及肿瘤发生发展过程中的作用逐渐被揭示,细胞自噬防止坏死引起的无菌性炎性反应和巨噬细胞浸润,不仅可以限制肿瘤细胞生长,同时也可以抑制肿瘤侵袭转移[9-11],GFP-LC3目前被认为是自噬体特异性标签,是一种检测自噬发生常用的实验技术手段。

    为了深入了解宫颈癌发生发展的分子机制和寻找新的治疗靶点,我们通过对miR-216b在宫颈癌细胞中作用的研究,为寻求宫颈癌特异性靶向诊断和治疗提供新的思路。

    人宫颈癌细胞系HeLa购自中国科学院上海细胞库;RPMI 1640细胞培养液及胎牛血清购自美国Life Technologies公司;GFP-LC3质粒由南京大学医学院惠赠。雷帕霉素、Beclin-1、LC-3B、GAPDH等抗体购自美国Santa Cruz公司;胰蛋白酶与胎牛血清购自美国Gibco公司;miR-216b引物、mimic和inhibitor及内参U6均购自广州锐博生物科技有限公司,转染所用阳离子脂质体LipofectamineTM 3000及Opti-MEM购自美国Invitrogen公司。

    将HeLa细胞接种到24孔板内,培养过夜,使细胞密度达到70%~80%。通过LipofectamineTM 3000转染GFP-LC3质粒体,6 h后换完全培养液继续培养24 h,之后将miR-216b mimic或inhibitor分别转染48 h,阳性对照组给予5 μmol/L雷帕霉素处理24 h。将处理后的细胞用PBS清洗3次,用4%多聚甲醛室温固定15 min,PBS清洗3次,荧光显微镜下观察,统计GFP-LC3的阳性自噬点数,统计对照组和处理组单个细胞中GFP-LC3荧光点数,每组至少统计60个细胞。

    将HeLa细胞均匀接种于60 mm培养皿中,药物处理后用预冷的PBS洗3遍,加入含有100 mmol/L PMSF的裂解液(RIPA)裂解细胞,冰上放置30 min充分裂解,4℃条件下12 000 r/min离心15 min,取上清液后经BCA法测定蛋白浓度。依次进行质量分数10%的SDS-PAGE凝胶电泳,使用PVDF转膜,5%脱脂奶粉封闭2 h后,4℃封闭一抗过夜,TBST清洗3次(每次5 min)后加入相应二抗,室温下孵育60 min,TBST洗3次后进行显影,实验重复三次,采用计算机软件ImageJ分析灰度值并记录。

    6孔板内接种HeLa细胞各6×105个。待细胞完全贴壁后用miR-216b inhibitor转染48 h,TRIzol试剂裂解细胞,按照试剂说明书提取基因组总RNA,取<0.5 μg RNA为模板进行反转录合成cDNA。按照说明书混合PCR反应体系(SYBRGreen),每管分别加入1 μl cDNA产物,仪器设置条件为:95℃ 10 min;95℃ 15 s,60℃ 1 min,共计40个循环。

    构建pmirGLO荧光素酶质粒报告系统(美国Promega公司)分析miRNA与预测靶序列的结合,该质粒含有两个不同荧光素酶基因,一个为插入Beclin-1 3’UTR序列的荧光素酶基因表达载体(野生型),另一个基因为靶结合位点突变的载体质粒(突变型)。将两种质粒分别与miR-216b mimic及其阴性对照共转染HeLa细胞,每组设5个复孔,培养48 h后进行荧光素酶相对活性检测,双荧光素酶报告实验(Dual Luciferase report assay)(美国Promega公司)上机检测。

    采用SPSS19.0统计学软件进行统计分析,经K-S检验,本研究各检测指标的数据资料呈正态分布,以均数±标准差表示,组间均数经Levene检验方差齐。采用均衡分组单因素干预多水平实验设计,处理因素作用总体差异比较均采用单因素方差分析,两两比较分别采用LSD-t检验和SNK-q检验。P<0.05被认为差异具有统计学意义。

    HeLa细胞转染GFP-LC3后,再转染miR-216b mimic,以雷帕霉素作为阳性对照,在荧光显微镜下观察并对带有GFP-LC3的自噬点阳性细胞数和总细胞数进行统计。相对于对照组和雷帕霉素组的细胞,miR-216b能够明显降低细胞自噬体的数量,见图 1。Western blot检测结果显示,自噬标记蛋白Beclin1表达量减少,作为自噬发生指标的LC3-Ⅱ/LC3-I比值也同样表现出下降;miR-216b能够降低HeLa细胞自噬蛋白的表达水平,见图 2。综上结果表明,miR-216b能够抑制HeLa细胞的自噬水平。

    图  1  荧光显微镜观察经miR-216b转染或雷帕霉素处理后HeLa细胞中GFP-LC3自噬点的分布变化
    Figure  1  Distribution of GFP-LC3 autophagy points in HeLa cells after transfection of miR-216b or rapamycin treatment observed by fluorescence microscopy
    A: the autophagy positive cells in normal control group,miR-216b mimic group and rapamycin group were observed by fluorescence microscope. Bright green fluorescent spots represented autophagy positive cells and the pictures below were for low power lens to corresponding groups;B: Autophagy positive cell rates in normal control group,miR-216b mimic group and rapamycin group (*: P<0.05)
    图  2  Western blot检测miR-216b抑制细胞自噬水平
    Figure  2  Cell autophagy inhibited by miR-216b detected by Western blot
    A: the expression of Beclin-1,LC3-Ⅰ and LC3-Ⅱ in normal control group,miR-216b mimic group and rapamycin group detected by Western blot; B: the ratio of LC3-Ⅱ/LC3-Ⅰ in normal control group,miR-216b mimic group and rapamycin group (*: P<0.05)

    转染miR-216b抑制剂的细胞中,miR-216b表达量出现明显下降,下降近80%。同时,其自噬点阳性细胞数明显增多,见图 3。通过Western blot检测发现,自噬相关蛋白Beclin-1和LC3-Ⅱ的表达均表现出增加,见图 4。结果表明,在HeLa细胞中,抑制miR-216b的表达能够促进自噬水平的升高。

    图  3  荧光显微镜观察经miR-216b抑制剂转染处理后HeLa中GFP-LC3自噬点的分布变化
    Figure  3  Distribution of GFP-LC3 autophagy points in HeLa cells after transfection with miR-216b inhibitor observed by fluorescence microscopy
    A: the expression of miR-216b in anti-NC group and anti-miR-216b group after transfection with miR-216b inhibitors; B: the positive rate of autophagy points in anti-NC group and anti-miR-216b group after transfection with miR-216b inhibitor; C: the autophagy positive cells in anti-NC group and anti-miR-216b group observed by fluorescence microscope after transfection with miR-216b inhibitor. Bright green fluorescent spots represented autophagy positive cells
    图  4  Western blot检测发现抑制miR-216b表达能够促进细胞自噬水平
    Figure  4  Inhibiting miR-216b expression could promote cells autophagy level observed by Western blot
    A: the expression of Beclin-1,LC3-Ⅰ,LC3-Ⅱ in anti-NC group and anti-miR-216b mimic group after transfection with miR-216b inhibitors detected by Western blot; B: the ratio of LC3-Ⅱ/LC3-Ⅰ in NC-anti group and anti-miR-216b mimic group after transfection with miR-216b inhibitors (*: P<0.05)

    查找数据库发现,miR-216b能够与Beclin-1的3’UTR区域中的579-585段结合,见图 5结果显示。两种质粒分别与miR-216b mimic及其阴性对照共转染HeLa细胞,48 h后将细胞裂解,通过荧光素值检测发现,转染Beclin-1 3’UTR质粒载体(野生组)和miR-216b组,其荧光素值相对于对照组明显下降,而Beclin-1 3’UTR突变位点组(突变组)荧光素值相对于对照组,未出现明显变化,见图 6。 结果表明,miR-216b能够通过靶结合Beclin-1中的3‘UTR区域中的579~585段发挥其抑制作用。

    图  5  数据库分析miR-216b能够靶结合Beclin-1 3’UTR序列
    Figure  5  miR-216b could targetedly binding Beclin-1 3'UTR sequence analyzed by database
    图  6  荧光素酶报告基因检测miR-216b能够靶结合Beclin-1 3’UTR
    Figure  6  miR-216b could targetedly binding Beclin-1 3'UTR detected by Luciferase

    MicroRNAs是真核生物细胞中一类长度约为17~24个核苷酸的内源性非编码小RNA。它本身不编码蛋白质,主要通过负性调控靶基因的表达发挥作用。近年来研究表明,某些miRNA的差异性表达与宫颈癌的发生、进展有密切关系,可以作为宫颈癌的诊断及预后的指标。宫颈癌中miRNA表达的失调与肿瘤的增殖、凋亡、侵袭和转移有重要关系[3-5]

    近年来miRNA在调节肿瘤自噬水平方面受到广泛关注,在维持细胞内环境稳定方面起着重要作用。本实验中,通过Western blot和GFP-LC3 shRNA转染细胞等检测方法,首次发现miR-216b能够显著降低HeLa细胞自噬水平,而施加miR-216b抑制剂后可明显提高自噬水平。本实验所选取的自噬相关蛋白-微管相关蛋白1轻链3(microtubule-associated protein 1 light chain 3,LC3)是目前研究较多的自噬标志性物质,其定位于前自噬泡和自噬泡膜表面,参与自噬体的形成,被认为是自噬特异性形成指标;Beclin-1是哺乳动物的自噬调控基因,是自噬发生的触发器,其表达的上调可诱导自噬的形成,可通过促进细胞凋亡诱导细胞自噬而抑制肿瘤的发展过程[12]。两种自噬指示蛋白在转染miR-216b mimic的作用下,均出现表达量降低。然而,转染miR-216b抑制剂后,自噬水平出现了上调,这与前述结果吻合,说明miR-216b的确能够抑制宫颈癌细胞的自噬水平。为进一步研究miR-216b在自噬过程中的功能,本研究通过荧光素酶报告基因的检测发现miR-216b能够靶结合Beclin-1的3’UTR区域,进而发挥其抑制作用。

    Beclin-1是酵母菌ATG6在哺乳类动物的同源基因,是第一个被发现参与自噬过程的基因,其编码的Beclin-1蛋白可调控自噬前体的形成,引导相关蛋白定位于自噬体膜[13]。体外研究发现,Beclin-1缺失的小鼠自发和病毒诱导的肿瘤发生率增加[14-15],说明Beclin-1在抑制肿瘤发生方面有重要作用。本实验发现miR-216b能够负调控Beclin-1的表达来影响宫颈癌细胞自噬水平。

    越来越多的研究发现机体细胞自噬活性变化对肿瘤的发生发展及对抗肿瘤药物的药效影响具有双重作用。研究发现自噬相关蛋白在宫颈癌中表达受抑制,下调自噬的形成,促进肿瘤的发生和发展[16],另外,也有研究发现,当自噬相关蛋白过表达后,宫颈癌细胞的生长会受到明显抑制[17],因此,通过调控自噬形成有可能成为未来宫颈癌治疗的策略之一,而本实验所研究的miR-216b的功能就是能够抑制宫颈癌细胞自噬的形成。宫颈癌是威胁女性健康的恶性肿瘤,目前,仍无有效的治疗方式。而自噬是维持细胞稳态的重要通路,在疾病中的作用逐步得到认同。本研究首次表明了miR-216b在宫颈癌自噬发生过程中的机制,为治疗宫颈癌提供了理论基础,也为开发类似药物提供了新的思路。

  • [1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-86.
    [2] Chen WQ, Zhang SW, Zeng HM, et al. Report of cancer incidence and mortality in China, 2010[J]. Zhongguo Zhong Liu, 2014, 23 (1): 1-10. [陈万青, 张思维, 曾红梅, 等. 中国2010年恶性肿瘤 发病与死亡[J]. 中国肿瘤, 2014, 23(1): 1-10.]
    [3] Gao GY. Health economics analysis of typical cases[M]. Beijing: People Health Publishing House, 2011, 1. [高广颖. 卫生经济学典 型案例分析[M]. 北京: 人民卫生出版社, 2011, 1.]
    [4] Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects[J]. Hepatobiliary Pancreat Dis Int, 2002, 1( 1): 35-41.
    [5] Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials[J]. World J Gastroenterol, 2003, 9(4): 63 5-40.
    [6] Chen XH, Zhang BH, Qiu SJ, et al. Effect of postoperative adjuvant transarterial chemoembolization on late recurrence of hepatocellular carcinoma after radical resection[J]. Zhonghua Gan Zang Bing Za Zhi, 2010, 18(8): 599-603. [陈晓泓, 张博恒, 邱双 健, 等. 肝细胞癌根治术后辅助性肝动脉化疗栓塞对远期复发 的影响[J]. 中华肝脏病杂志, 2010, 18(8): 599-603.]
    [7] Shen L, Zhu HC, Huang JF, et al. Survival analysis of 108 cases with advanced primary liver cancer treated by transcatheter arterial chemoembolization[J]. Zhong Liu Fang Zhi Yan Jiu, 2011, 38(10): 11 63-6.[沈玲, 朱海超, 黄建锋, 等. TACE治疗中晚期原发性肝 癌108例生存分析[J]. 肿瘤防治研究, 2011, 38(10): 1163-6.]
    [8] Chen XH, Zhang BH, Qiu SJ, et al. Effect of postoperative adjuvant transarterial chemoembolization upon early recurrence after radical resection of hepatocellular carcinoma[J]. Zhonghua Gan Zang Bing Za Zhi, 2010, 90(12): 826-9. [陈晓泓, 张博恒, 邱 双健, 等. 肝细胞癌根治术后辅助性肝动脉化疗栓塞对近期复 发的影响[J]. 中华肝脏病杂志, 2010, 90(12): 826-9.]
    [9] Ministry of Health of the People's Republic of China ([2011]121). Primary liver cancer diagnosis and treatment standard (2011 Edition)[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2011, 16(10): 92 9-46. [中华人民共和国卫生部. 原发性肝癌诊疗规范(2011 年版) [J]. 临床肿瘤学杂志, 2011, 16(10): 929-46.]
    [10] Gao GY. Health economics analysis of typical cases[M]. Beijing: People Health Publishing House, 2011: 258. [高广颖. 卫生经济 学典型案例分析[M]. 北京: 人民卫生出版社, 2011: 258.]
    [11] Gu H, Li HC. Study of the related problems in the application of the cost-effectiveness analysis in pharmacoeconomics[J]. Zhongguo Yao Fang, 2004, 15(11): 674-6. [顾海, 李洪超. 药物经济学成本-效 果分析应用的相关问题探讨[J]. 中国药房, 2004, 15(11): 674-6.]
    [12] Gao GY. Health economics analysis of typical cases[M]. Beijing: People Health Publishing House, 2011: 259. [高广颖. 卫生经济学典 型案例分析[M]. 北京: 人民卫生出版社, 2011: 259.]
    [13] Gunay Y, Guler N, Akyildiz M, et al. Management of patients with recurrent hepatocellular carcinoma following living donor liver transplantation: a single center experience[J]. Gulf J Oncolog, 20 14, 1(15): 12-8 .
    [14] Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence[J]. Ann Surg, 20 03, 237(4): 536-43 .
    [15] Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome[J]. Liver Transpl, 20 04, 10(2 Suppl 1): S39-45 .
    [16] Jiang QC, Li SH. Health economics courses[M]. Hefei: Anhui Science and Technology Publishing House, 2002: 266-86. [江启 成, 李绍华. 卫生经济学教程[M]. 合肥: 安徽科学技术出版社, 20 02: 266-86.]
    [17] Liu Q. Analysis of commonly used evaluation methods of medical economics[J]. Zhongguo Xian Dai Yi Xue Za Zhi, 2009, 19(12): 19 13-5. [刘勤. 卫生经济学常用评价方法浅析[J]. 中国现代医 学杂志, 2009, 19(12): 1913-5.] .
    [18] Liu B, Zhao ZQ, Wang LL, et al. Forward evaluations of CBA in health economics[J]. Zhongguo Wei Sheng Jing Ji, 2006, 6(25): 75 -6. [刘柏, 赵振全, 汪玲丽, 等. 卫生经济成本效果分析的前 沿评价方法研究[J]. 中国卫生经济, 2006, 6(25): 75-6.]
    [19] Gao GY. Health economics analysis of typical cases[M]. Beijing: People Health Publishing House, 2011: 262. [高广颖. 卫生经济学 典型案例分析[M]. 北京: 人民卫生出版社, 2011: 262.]
计量
  • 文章访问数:  1523
  • HTML全文浏览量:  348
  • PDF下载量:  37929
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-12-01
  • 修回日期:  2015-02-08
  • 刊出日期:  2015-04-24

目录

/

返回文章
返回
x 关闭 永久关闭